Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Phase 1 Active not recruiting 161 enrolled ModernaTX, Inc. Merck Sharp & Dohme LLC · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.

Timeline

Start: 2017-08-14
Primary completion: 2027-11-21
Completion: 2027-11-21

Publications

Berraondo P, Cuesta R, Sanmamed MF, Melero I. Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines. Cancer Discov. 2024 Nov 1;14(11):2021-2024. doi: 10.1158/2159-8290.CD-24-1196.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Intismeran autogene	Messenger RNA (mRNA)	—	Intramuscular
Subject	Pembrolizumab	Monoclonal antibody	—	Intravenous

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications